The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.

C.J. Hoekstra, SG Stroobants, O.S. Hoekstra, J Vansteenkiste, B. Biesma, FJ Schramel, N. van Zandwijk, H. van Tinteren, E.F. Smit

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)151-7
JournalLung Cancer
Issue number2
Publication statusPublished - 2003

Cite this